Quote Request
RNA-Based Therapy Development for Pancreatic Cancer
RNA-based therapies offer distinct advantages over DNA-based therapies, including reduced risk of genomic integration and faster cellular response. Alfa Cytology's primary objectives include the development of innovative RNA-based therapeutics, detailed preclinical evaluations, and optimization of delivery mechanisms to support breakthrough research in the field of PC therapy.
Introduction to RNA-Based Therapeutic Technology
RNA therapeutics comprise a rapidly evolving class of drugs that hold the promise of combating many previously untreatable diseases, including infectious diseases, cancers, neurodegenerative disorders, metabolic disorders, and rare genetic disorders, as well as enabling personalized medicine. Much of this hope rests on the fundamental cellular role of RNA as a template, catalyst, scaffold, or regulator.
Fig. 1 Schematic illustrating different classes of RNA therapeutics. (Damase TR, et al, 2021)
The main features of RNA gene therapy include:
- Specificity: All RNA-based therapies are designed to target specific mRNA sequences, ensuring precise modulation of gene expression.
- Versatility: The ability to design and synthesize RNA molecules for nearly any gene makes these therapies highly adaptable to different diseases.
- Transient Effects: RNA-based therapies generally provide temporary gene modulation, reducing risks associated with permanent genetic changes.
Our Services
Our comprehensive one-stop service includes the full spectrum of RNA-based therapy development for pancreatic cancer. This encompasses initial concept design, custom RNA synthesis, formulation optimization, in vitro and in vivo efficacy studies, toxicity assessments, and data analysis to ensure the development of robust therapeutic candidates.
RNA-Based Therapy Type We Develop
Antisense Oligonucleotide (ASO)
Developing ASOs to specifically bind and degrade target mRNA, silencing oncogenes in pancreatic cancer. Services include custom ASO design, synthesis, stability optimization, and preclinical efficacy testing.
Development of miRNA-based therapeutics, including miRNA mimics and inhibitors, to modulate gene expression networks involved in pancreatic cancer. Services include custom miRNA design, synthesis, and functional validation in preclinical models.
Design and development of aptamers, short single-stranded nucleic acids that bind specific targets with high affinity, for targeted therapy and diagnostic applications in pancreatic cancer. Services encompass aptamer selection, optimization, and functional characterization.
Targeting circRNAs can regulate not only a wide range of oncogenes but also miRNAs. Our services include circRNA design and optimization, circRNA chemical manufacturing and control (CMC), and circRNA-based drug delivery systems development.
Why Choose Us?
Tailored Solutions
Advanced Technology
Professional Expertise
Collaborative Approach
Alfa Cytology is committed to advancing pancreatic cancer research with cutting-edge RNA-based therapeutic technologies that offer precision, reduced off-target effects, and innovative treatment pathways. Please do not hesitate to contact us to discuss how our one-stop-shop can facilitate breakthrough discoveries in pancreatic cancer treatment.
Reference
- Damase TR, et al. The Limitless Future of RNA Therapeutics. Front. Bioeng. Biotechnol. 2021, 9:628137.
